Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avner Reshef

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Allergy|January 30, 2026
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary AngioedemaHenriette Farkas, Inmaculada Martinez-Saguer, Konrad Bork, et al.
Clinical Reviews in Allergy & Immunology|March 7, 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and TreatmentBruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
Arerugi = [Allergy]|April 12, 2026
Bruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine|March 23, 2017
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorHilary Longhurst, Marco Cicardi, Timothy Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 12, 2024
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary AngioedemaRemy S Petersen, Lauré M Fijen, Christian Apfelbacher, et al.
The New England Journal of Medicine|September 8, 2010
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedemaMarco Cicardi, Aleena Banerji, Francisco Bracho, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|July 30, 2010
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaTom Bowen, Marco Cicardi, Henriette Farkas, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|March 3, 2023
Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trialTimothy J Craig, Avner Reshef, H Henry Li, et al.
Allergy|January 30, 2026
International Guideline on the Diagnosis and Management of Pediatric Patients With Hereditary AngioedemaHenriette Farkas, Inmaculada Martinez-Saguer, Konrad Bork, et al.
Clinical Reviews in Allergy & Immunology|March 7, 2025
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and TreatmentBruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
Arerugi = [Allergy]|April 12, 2026
Bruce L Zuraw, Konrad Bork, Laurence Bouillet, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 18, 2019
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema AttacksTimothy Craig, Bruce Zuraw, Hilary Longhurst, et al.
The Lancet. Haematology|March 22, 2026
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trialMarcus Maurer, Marcin Stobiecki, Anna Valerieva, et al.
The New England Journal of Medicine|March 23, 2017
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorHilary Longhurst, Marco Cicardi, Timothy Craig, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 12, 2024
A Core Outcome Set for Efficacy of Acute Treatment of Hereditary AngioedemaRemy S Petersen, Lauré M Fijen, Christian Apfelbacher, et al.
The New England Journal of Medicine|September 8, 2010
Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedemaMarco Cicardi, Aleena Banerji, Francisco Bracho, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|July 30, 2010
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaTom Bowen, Marco Cicardi, Henriette Farkas, et al.
Pageof 7